Other languages 2seventy bio, Inc.

Equities

TSVT

US9013841070

Market Closed - Nasdaq Other stock markets 01:30:00 02/05/2024 am IST			5-day change	1st Jan Change
4.6 ^USD	+0.88%		+7.73%	+7.73%

19/04	US FDA mandates label updates on CAR-T cancer therapies	RE
05/04	Bristol-Myers Squibb, 2seventy Bio Say FDA Approves Expansion of Myeloma Treatment's Indication	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

US FDA mandates label updates on CAR-T cancer therapies	19/04
Bristol-Myers Squibb, 2seventy Bio Say FDA Approves Expansion of Myeloma Treatment's Indication	05/04
Bristol Myers : la FDA valide Abecma dans le myélome multiple	05/04
US FDA allows expanded use of Bristol Myers' cell therapy for blood cancer	05/04
U.S. FDA allows expanded use of Bristol Myers' cell therapy	05/04
U.S. Fda Approves Bristol Myers Squibb and 2Seventy Bio?S Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy	05/04
Regeneron Pharmaceuticals, Inc. completed the acquiistion of R&D pipeline from 2seventy bio, Inc..	01/04
Regeneron Pharmaceuticals, Inc. completed the acquiistion of R&D pipeline from 2seventy bio, Inc. for $15 million.	01/04
2seventy bio, Inc. Announces Board Appointments	21/03
Top Premarket Gainers	18/03
FDA Advisory Committee Votes in Favor of Bristol-Myers Squibb Company and 2seventy bio, Inc. Abecma for Triple-Class Exposed Multiple Myeloma in Further Lines of Therapy	16/03
US FDA panel votes in favor of expanded use of Bristol Myers' CAR-T therapy	16/03
US FDA staff flag safety concerns from J&J, Bristol's CAR-T therapies	13/03
2seventy bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05/03
2seventy bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	05/03
Bristol-Myers Squibb, 2seventy bio's Supplemental BLA Application for Abecma Expected to be Reviewed by US FDA March 15	05/02
Bristol Myers : la FDA va étudier Abecma comme soin du myélome	05/02
Bristol Myers Squibb and 2seventy bio, Inc. Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study	05/02
2seventy bio to Sell Investigational Cell Therapies to Regeneron Amid Restructuring	30/01
2seventy bio, Inc. Announces CEO Changes	30/01

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages 2seventy bio, Inc.

Equities

TSVT

US9013841070

Other languages

Filters